An article Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes WOS:000566953100021 published article about FIBRILLATION; PREVALENCE in [Weng, Willy; Wiefels, Christiane; Nery, Pablo B.; Celiker-Guler, Emel; Promislow, Steven; Medor, Maria C.; Spence, Stewart; Odabashian, Roupen; Alqarawi, Wael; Juneau, Daniel; de Kemp, Rob; Leung, Eugene; Beanlands, Rob; Birnie, David] Univ Ottawa, Heart Inst, Div Cardiol, 40 Ruskin St, Ottawa, ON K1Y 4W7, Canada; [Chakrabarti, Santabhanu] Univ British Columbia, Div Cardiol, Vancouver, BC, Canada; [Healey, Jeff S.] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada; [Hruczkowski, Tomasz W.] Univ Alberta, Mazankowski Alberta Heart Inst, Edmonton, AB, Canada; [Quinn, F. Russell] Libin Cardiovasc Inst Alberta, Calgary, AB, Canada; [Juneau, Daniel] Univ Montreal, Ctr Hosp, Dept Nucl Med & Radiol, Montreal, PQ, Canada in 2020.0, Cited 19.0. The Name is 2,2′-Disulfanediyldiethanamine dihydrochloride. Through research, I have a further understanding and discovery of 56-17-7. Recommanded Product: 2,2′-Disulfanediyldiethanamine dihydrochloride
Background: Recent data have suggested a substantial incidence of atrial arrhythmias (AAs) in cardiac sarcoidosis (CS). Our study aims were to first assess how often AAs are the presenting feature of previously undiagnosed CS. Second, we used prospective follow-up data from implanted devices to investigate AA incidence, burden, predictors, and response to immunosuppression. Methods and Results: This project is a substudy of the CHASM-CS (Cardiac Sarcoidosis Multicenter Prospective Cohort Study; NCT01477359). Inclusion criteria were presentation with clinically manifest cardiac sarcoidosis, treatment-naive status, and implanted with a device that reported accurate AA burden. Data were collected at each device interrogation visit for all patients and all potential episodes of AA were adjudicated. For each intervisit period, the total AA burden was obtained. A total of 33 patients met the inclusion criteria (aged 56.1 +/- 7.7 years, 45.5% women). Only 1 patient had important AAs as a part of the initial CS presentation. During a median follow-up of 49.1 months, 11 of 33 patients (33.3%) had device-detected AAs, and only 2 (6.1%) had a clinically significant AA burden. Both patients had reduced burden after CS was successfully treated and there was no residual fluorodeoxyglucose uptake on positron emission tomography scan. Conclusions: First, we found that AAs are a rare presenting feature of clinically manifest cardiac sarcoidosis. Second, AAs occurred in a minority of patients at follow-up; the burden was very low in most patients. Only 2 patients had clinically significant AA burden, and both had a reduction after CS was treated. REGISTRATION: URL: https://www.clinicaltrials.gov; unique identifier NCT01477359.
Welcome to talk about 56-17-7, If you have any questions, you can contact Weng, W; Wiefels, C; Chakrabarti, S; Nery, PB; Celiker-Guler, E; Healey, JS; Hruczkowski, TW; Quinn, FR; Promislow, S; Medor, MC; Spence, S; Odabashian, R; Alqarawi, W; Juneau, D; de Kemp, R; Leung, E; Beanlands, R; Birnie, D or send Email.. Recommanded Product: 2,2′-Disulfanediyldiethanamine dihydrochloride
Reference:
Thiazine – an overview | ScienceDirect Topics,
,Thiazine | C4H5NS – PubChem